All GLG News Analyses Filed Under: Business of Medicine

There are some new developments for Average Manufacturer Price (AMP), although the situation has now devolved into a somewhat arcane legal battle. Unless there is a legislative fix (unlikely), then I expect that Center for Medicare and Medicaid Services (CMS) will punt this issue to the next administration...

Mipomersen (formerly known as ISIS 301012) is a in class of novel therapeutic agents that reduce the production of a protein in the liver that is responsible for cholesterol production. It is though that inhibiting that production on a molecular level would decrease the levels of cholesterol. Mipomersen...

First, and foremost, the only working link for this article can be found at: http://www.reuters.com/article/domesticNews/idUSWAT00934620080415?feedType=RSS&feedName=domesticNews Although there is no proof offered in the article to substantiate the suggestion of fraud, there is enough circumstantial...

Allowing "generic" versions of biotech drugs to market without full safety testing would endanger consumers

One only has to read about the Heparin debacle, which has killed, at least, 81 Americans, to realize that there is a serious issue with the quality of medicines produced in China.  Manufacturing of medical food and consumer goods in China is growing at such a rate, the Chinese government has neither...

It's easy to point fingers of blame and this article does that, very well.  According to the "annalysis" everybody is to blame.  And, they're right, everyone is to blame, but where the article fails is the authoris inability to point out a real solution to the problem of wasted dollars spent...

Situins are enzymes that regulate predetermined cell death, activity in muscle and fat cells as well as energy expenditure. There are several classes of these enzymes (SIRT 1 through 7). The technology is promising in that it promises to regulate some of the causes of diabetes and obesity rather than...

For the first time a major comprehensive authoritative national study (by PricewaterhouseCoopers, LLP) has concluded that over one half of the nation's $2.2 trillion in annual health spending (fully $1.2 trillion) is wasted.  Other studies have put this percentage in the 25 to 40% range. ...

The USPTO’s proposed rule changes, struck down in this important Glaxo federal court decision, would have added significant burdens to pharmaceutical companies in developing their IP portfolios and ultimately their drug treatments.   The proposed changes were seemingly motivated to make the...

The USPTO is facing an epidemic amount of frivolous patents.  This degrades their ability to review strong and potentially important patents in a timely manner.  Although this particular change was struck down in Federal court, industry leaders need to work with the USPTO in order...